UroGen Pharma (FRA:UR8) ROCE % : -74.26% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is UroGen Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. UroGen Pharma's annualized ROCE % for the quarter that ended in Mar. 2024 was -74.26%.

UroGen Pharma ROCE % Historical Data

The historical data trend for UroGen Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UroGen Pharma ROCE % Chart

UroGen Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-80.83

-84.26

-114.66

-98.13

-63.80

UroGen Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-106.23	-103.31	-61.41	-46.64	-74.26

UroGen Pharma ROCE % Calculation

UroGen Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-76.669	/	( ( (128.024 - 22.577)	+	(163.511 - 28.621) )	/ 2 )
	=	-76.669	/	( (105.447	+	134.89)	/ 2 )
	=	-76.669	/	120.1685
	=	-63.80 %

UroGen Pharma's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-109.608	/	( ( (163.511 - 28.621)	+	(184.528 - 24.233) )	/ 2 )
	=	-109.608	/	( ( 134.89	+	160.295 )	/ 2 )
	=	-109.608	/	147.5925
	=	-74.26 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

UroGen Pharma (FRA:UR8) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

UroGen Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

UroGen Pharma (FRA:UR8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (FRA:UR8) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

URGN:USA

Address

400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540

Website

https://www.urogen.com

UroGen Pharma Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.

UroGen Pharma (FRA:UR8) Headlines

No Headlines